Monday morning, On April 1, Pfizer Inc (PFE) announced results of its tender offer by its wholly-owned subsidiary, Explorer Acquisition Corp., to purchase all of the outstanding shares of common stock of Encysive Pharmaceuticals Inc. (ENCY) at a $2.35 per share, net to the seller in cash, without interest thereon and less any required withholding taxes.Pfizer said that a total of 70,238,869 shares or about 86.8% of the outstanding shares, including 8,473,574 shares subject to guarantees of delivery, were validly tendered prior to the expiration of the initial offering period, which occurred at 12 midnight, New York City time, on March 31.The period for delivery of shares pursuant to guaranteed delivery procedures expired on April 3, at 5 p.m., New York City time, and, as of such time, a total of 2,363,384 shares were validly tendered.As of April 1, Pfizer said it beneficially owned about 64,128,679 shares, representing about 79.22% of the outstanding shares.Pfizer also announced that Explorer Acquisition commenced a subsequent offering period to acquire all of the remaining untendered shares that will expire at 5:00 p.m., New York City time, on April 7, unless extended. Georgeson is acting as the Information Agent for the tender offer.PFE is currently down $0.05 and trades at $21.30. ENCY is presently down $0.01 and trades at $2.34.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.